These model mice are useful for clarifying and characterizing the final outcome of brain abnormalities in dystroglycanopathy, but the analysis of disease onset is limited due to the residual effects of dystroglycan produced before Cre-mediated inactivation. Here, DAG1 is linked to neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.